Business Context and Reporting Period
This Form 8-K, dated February 13, 2025, reports on the special meeting of stockholders held by Bellevue Life Sciences Acquisition Corp. (BLAC), which is transitioning to OSR Holdings, Inc. The filing details the approval of a business combination, amendments to the certificate of incorporation, and the election of a new board of directors.
Key Financial Metrics and Voting Results
The filing does not provide standard financial metrics such as revenue, profit, cash flow, or debt levels, as it focuses on corporate governance and transaction approval. Key quantitative data points include:
- Shares Outstanding: 2,319,752 shares of common stock as of the January 27, 2025 record date.
- Voting Participation: 2,179,383 shares (93.95% of voting power) were represented at the meeting.
- Redemptions: 57,821 shares of common stock were tendered for redemption in connection with the vote.
- Approval Margin: Proposals 1, 2, 3A-3F, 4, 5, and 6 received 2,175,065 votes "For" and 4,318 votes "Against" or "Withhold."
Material Changes
The following material changes were approved by stockholders:
- Business Combination: Approval of the Amended and Restated Business Combination Agreement dated May 23, 2024 (as amended December 20, 2024).
- Corporate Name: Change of name from Bellevue Life Sciences Acquisition Corp. to OSR Holdings, Inc.
- Capital Structure: Increase in authorized preferred stock from 1,000,000 to 20,000,000 shares.
- Governance: Adoption of an Amended and Restated Certificate of Incorporation and Bylaws, including changes to director removal thresholds (requiring 66 2/3% vote), quorum requirements (reduced to one-third of voting power), and elimination of corporate opportunity limitations.
- Leadership: Election of nine new directors to serve following the closing of the business combination.
Outlook, Risks, and Unusual Items
The filing confirms the successful passage of all necessary proposals to proceed with the business combination. No specific financial guidance, risk factors, or unusual items are detailed within this specific 8-K text, as the document serves as a report of the voting outcome and corporate amendments. The filing notes that the communication does not constitute an offer to sell securities.
Investor Verification Checklist
- Verify the final closing date of the Business Combination and the post-transaction share count.
- Review the full Amended and Restated Certificate of Incorporation (Exhibit 3.1) for specific governance implications.
- Confirm the impact of the 57,821 redemptions on the company's cash position and trust account.
- Examine the new omnibus incentive plan (Annex H of the Proxy Statement) for potential dilution effects.
- Check the press release (Exhibit 99.1) for management commentary on the transaction's strategic rationale.